Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,148.00    22.00 (1.03%)
Bid:
2,144.00
Ask:
2,154.00
Spread: 10.00 (0.466%)
Market Cap: £1.43b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Director/PDMR Shareholding

22 Sep 2010 14:49

RNS Number : 1319T
Genus PLC
22 September 2010
 

22 September 2010

 

Genus plc

 

('Genus' or 'the Company')

 

Director/PDMR Shareholding

 

 

Genus announces that conditional nil-cost share options were granted under the Genus 2004 Performance Share Plan ("the Plan") today to Richard Wood, Chief Executive, as to 57,631 ordinary shares of 10 pence each in the Company ("Ordinary Shares"). These options are subject to performance conditions which relate to growth in the Company's earnings per share over a three year period and which trigger vesting on an incremental basis.

 

Genus further announces that of 154,639 Ordinary Shares that vested today in favour of Richard Wood, Chief Executive, under the Plan, 154,639 Ordinary Shares were today sold on behalf of Richard Wood at a price of 770 pence per Ordinary Share.

 

Richard Wood's direct shareholding in the Company stands at 60,856 Ordinary Shares which represents 0.102% of the issued share capital of the Company which is currently 59,678,535 Ordinary Shares. In addition, he remains the beneficial owner of 195,457 conditional nil-cost options under the Plan.

 

Genus also announces that of 34,364 Ordinary Shares that vested today in favour of Ian Biggs, Head of Global Product & Business Strategy, under the Plan, 34,364 Ordinary Shares were today sold on behalf of Ian Biggs at a price of 770 pence per Ordinary Share. Ian Biggs' direct shareholding in the Company stands at 3,375 Ordinary Shares which represents 0.006% of the issued share capital of the Company. In addition, he remains the beneficial owner of 109,530 conditional nil-cost options under the Plan.

 

Of 33,505 Ordinary Shares that vested today in favour of Thomas Philip Acton, Chief Operating Officer of Europe & The Far East, under the Plan, 33,505 Ordinary Shares were today sold on behalf of Thomas Philip Acton at a price of 770 pence per Ordinary Share.

Thomas Philip Acton's direct shareholding in the Company stands at 21,104 Ordinary Shares which represents 0.035% of the issued share capital of the Company. In addition, he remains the beneficial owner of 103,084 conditional nil-cost options under the Plan.

 

Of 17,182 Ordinary Shares that vested today in favour of Ian Farrelly, Group Company Secretary & General Counsel, under the Plan, 17,182 Ordinary Shares were today sold on behalf of Ian Farrelly at a price of 770 pence per Ordinary Share. Ian Farrelly has no direct shareholding in the Company. He remains the beneficial owner of 75,018 conditional nil-cost options under the Plan.

 

 

For further information please contact:

 

Cara Crichton

Company Secretarial Assistant

Genus plc

 

Tel: 01256 345996

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUUSORRWAKUAR
Date   Source Headline
8th Dec 20174:41 pmRNSDirector/PDMR Shareholding
1st Dec 20172:00 pmRNSTotal Voting Rights
23rd Nov 201710:57 amRNSDirector/PDMR Shareholding
17th Nov 20172:15 pmRNSAdditional Listing to Correct Discrepancy
16th Nov 20172:49 pmRNSResult of AGM
16th Nov 20177:00 amRNSAGM Trading Update
6th Nov 201712:48 pmRNSDirector/PDMR Shareholding
2nd Nov 20172:01 pmRNSNon-Executive Director Retirement
1st Nov 20172:00 pmRNSTotal Voting Rights
31st Oct 20177:00 amRNSAdditional Listing
12th Oct 201710:39 amRNSNotice of AGM
2nd Oct 20172:00 pmRNSTotal Voting Rights
29th Sep 20177:08 amRNSDirector Declaration
21st Sep 20175:29 pmRNSDirector/PDMR Shareholding - Replacement
14th Sep 20175:30 pmRNSDirector/PDMR Shareholding
7th Sep 20177:00 amRNSPreliminary Results
1st Sep 20173:12 pmRNSTotal Voting Rights
17th Aug 20172:51 pmRNSHolding(s) in Company
1st Aug 20172:00 pmRNSTotal Voting Rights
1st Aug 20172:00 pmRNSBlock listing Interim Review
3rd Jul 20172:59 pmRNSTotal Voting Rights
29th Jun 20175:23 pmRNSAdditional Listing
12th Jun 20173:23 pmRNSHolding(s) in Company
9th Jun 20177:00 amRNSUS LITIGATION UPDATE
2nd Jun 20177:00 amRNSTotal Voting Rights
1st Jun 20177:05 amRNSUpdate Regarding The Milk Pension Fund
2nd May 20173:00 pmRNSTotal Voting Rights
12th Apr 20174:48 pmRNSDirector/PDMR Shareholding
3rd Apr 20172:00 pmRNSTotal Voting Rights
3rd Apr 20177:00 amRNSSUCCESSFUL LEGAL OUTCOME FOR GENUS
15th Mar 20175:15 pmRNSDirector/PDMR Shareholding
15th Mar 201712:00 pmRNSDirector Declaration
1st Mar 201710:09 amRNSDirector/PDMR Shareholding
23rd Feb 20174:20 pmRNSCorrection of Record Date
23rd Feb 20177:00 amRNSAcquisition and strategic partnership
23rd Feb 20177:00 amRNSInterim Results
7th Feb 20174:00 pmRNSHolding(s) in Company
1st Feb 20172:00 pmRNSBlock listing Interim Review
13th Dec 20163:39 pmRNSDirector/PDMR Shareholding
1st Dec 20162:00 pmRNSTotal Voting Rights
17th Nov 20162:01 pmRNSResult of AGM
17th Nov 20167:00 amRNSAGM - Trading Update
1st Nov 20164:00 pmRNSTotal Voting Rights
31st Oct 20163:47 pmRNSAnnual Report and Annual General Meeting
26th Oct 20164:00 pmRNSHolding(s) in Company
11th Oct 20164:08 pmRNSDirector/PDMR Shareholding
3rd Oct 20166:09 pmRNSBlock Listing and Additional Listing
3rd Oct 20165:57 pmRNSTotal Voting Rights
29th Sep 20165:00 pmRNSDirector/PDMR Shareholding
15th Sep 20165:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.